• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    12/9/22 5:24:28 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    SC 13D/A 1 summit-sc13da_120622.htm AMENDMENT TO FORM SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D 

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 7)1

     

    Summit Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    86627T108

    (CUSIP Number)

     

    ADAM W. FINERMAN, ESQ.

    BAKER HOSTETLER LLP

    45 Rockefeller Plaza

    New York, New York 10111

    (212) 589-4233

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 6, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

       

     

    CUSIP No. 86627T108

                                           
      1   NAME OF REPORTING PERSON  
             
            ROBERT W. DUGGAN  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            U.S.A.  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         175,864,281*  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              175,864,281*  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            175,864,281*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            81.8%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

    * The 175,864,281 shares of Common Stock beneficially owned consist of (i) 162,532,792 shares of Common Stock previously owned by the Reporting Person, (ii) 9,346,434 shares of Common Stock, representing the number of shares of Common Stock issued to the Reporting Person as payment of interest in connection with the NPA (as defined below) and (iii) includes the exercise of warrants to buy 3,985,055 shares of Common Stock, which are exercisable until December 24, 2029.

     

     2 

     

    CUSIP No. 86627T108

     

     

     

    The following constitutes the Schedule 13D/A filed by the undersigned (as amended hereby, the “Schedule 13D”).

     

      Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended to add the following:

     

    The 9,346,434 Shares acquired by the Reporting Person were issued as payment of interest in connection with the NPA (as defined below). The determination of the number of shares to issue to the Reporting Person was based on a per share price of $0.79, for an aggregate value of $7,383,682.86. The aggregate purchase cost of the 171,879,226 Shares owned directly by Mr. Duggan is approximately $269,277,499, including brokerage commissions. Mr. Duggan also holds 3,985,055 warrants to purchase shares of Common Stock, which are exercisable until December 24, 2029. The Reporting Person paid such consideration using personal funds.

     

      Item 4. Purpose of Transaction.

     

    Item 4 is hereby amended to add the following:

     

    The Issuer entered into a Note Purchase Agreement (the “NPA”) on December 6, 2022 with Mr. Duggan and Dr. Maky Zanganeh. Pursuant to the NPA, the Issuer issued to Mr. Duggan in a private placement (the “Note Purchase”) an unsecured promissory note in the amount of $400 million and an unsecured promissory note in the amount of $100 million (collectively, the “Notes”), which will mature and become due on February 15, 2023 (the “February Maturity Date”) and September 15, 2023, respectively. All interest on the Notes was paid on the date of signing for the period through the February Maturity Date, and the prepaid interest was paid in a number of shares of Common Stock of the Issuer equal to the dollar amount of such prepaid interest, divided by the consolidated closing bid price immediately preceding the time the Issuer entered into the NPA, plus $.01 (approximately $0.79), which amounts to 9,720,291 shares.

     

    The foregoing summary of the NPA does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which are attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     

     3 

     

    CUSIP No. 86627T108

     

     

     

      Item 5. Interests in Securities of the Issuer.

     

    Items 5(a)-(c) are hereby amended and restated to read as follows:

     

    The aggregate percentage of Common Stock reported owned by the Reporting Person is based on 211,041,466 shares of Common Stock, which consists of (i) 201,321,175 shares of Common Stock outstanding as of November 2, 2022, which is the total number of shares of Common Stock disclosed by the Issuer in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2022 and (ii) 9,720,291 shares of Common Stock issued in connection with the Note Purchase..

     

      A. Mr. Duggan

     

      (a) As of the close of business on December 6, 2022, through the holding of (i) 171,879,226 shares of Common Stock and (ii) warrants to purchase 3,985,055 shares of Common Stock, the Reporting Person beneficially owns 175,864,281 shares of Common Stock (the “Shares”). Shares held by the Reporting Person include shares held in his retirement accounts.
         
        Percentage: Approximately 81.8%. 
         
      (b) 1. Sole power to vote or direct: 175,864,281
    2. Shared power to vote or direct: 0
    3. Sole power to dispose of or direct the disposition of: 175,864,281
    4. Shared power to dispose of or direct the disposition of: 0
         
      (c) Other than the 9,346,434 shares of Common Stock acquired pursuant to the Note Purchase, Mr. Duggan has not entered into any transactions in the Shares during the past sixty days.

     

      Item 6. Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

     

    Item 6 is hereby amended to add the following:

     

    The description of the Note Purchase as set forth in Item 4 is incorporated herein by reference. 

     

    Item 7.

    Materials to be Filed as Exhibits.

       
      99.1 Note Purchase Agreement dated December 6, 2022, by and among the Issuer, the Reporting Person, and Dr. Mahkam Zanganeh (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed on December 6, 2022).

      

     4 

     

    CUSIP No. 86627T108

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

     

    Dated: December 9, 2022

       
       
     

    /s/ Robert W. Duggan

      Robert W. Duggan

     

     

     5 

     

     

    Get the next $SMMT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    9/17/2025$13.00Underweight
    Barclays
    9/4/2025$40.00Buy
    Guggenheim
    8/19/2025$21.00Neutral
    Piper Sandler
    7/1/2025$30.00Buy
    UBS
    6/11/2025$12.00Underperform
    Leerink Partners
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    3/21/2025Overweight
    Cantor Fitzgerald
    3/12/2025$30.00Outperform
    Evercore ISI
    More analyst ratings

    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Summit Therapeutics with a new price target

    Barclays initiated coverage of Summit Therapeutics with a rating of Underweight and set a new price target of $13.00

    9/17/25 8:03:56 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Summit Therapeutics with a new price target

    Guggenheim initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $40.00

    9/4/25 9:07:53 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Summit Therapeutics with a new price target

    Piper Sandler initiated coverage of Summit Therapeutics with a rating of Neutral and set a new price target of $21.00

    8/19/25 8:35:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/19/25 4:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    3/27/24 8:28:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    SEC Filings

    View All

    SEC Form 10-Q filed by Summit Therapeutics Inc.

    10-Q - Summit Therapeutics Inc. (0001599298) (Filer)

    10/20/25 7:51:24 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Summit Therapeutics Inc.

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    10/20/25 7:28:51 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    9/8/25 7:45:14 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

    Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared

    10/20/25 6:45:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60 Tolerable Safety Profile Reaffirmed for PD-1 / VEGF Bispecific in Squamous NSCLC: Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation & Death Rates Were Observed in the Two Arms of HARMONi-6 Summit-Sponsored HARMONi-3 Global Study Will be Split into Two Analyses by Histology: Squamo

    10/19/25 10:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

    HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLC Clinical Trial Site Activations Planned to Begin This Quarter in the United States Conference Call to be Held at 8:00am ET on Monday, October 20, 2025 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compare

    10/17/25 7:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

    Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

    3/17/25 4:24:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

    6/27/24 4:15:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

    4/11/24 4:30:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SMMT
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

    Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared

    10/20/25 6:45:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60 Tolerable Safety Profile Reaffirmed for PD-1 / VEGF Bispecific in Squamous NSCLC: Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation & Death Rates Were Observed in the Two Arms of HARMONi-6 Summit-Sponsored HARMONi-3 Global Study Will be Split into Two Analyses by Histology: Squamo

    10/19/25 10:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

    HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLC Clinical Trial Site Activations Planned to Begin This Quarter in the United States Conference Call to be Held at 8:00am ET on Monday, October 20, 2025 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compare

    10/17/25 7:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    9/13/24 5:54:25 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    3/13/23 4:51:59 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    2/16/23 4:01:07 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care